Connexicon Medical Limited, a leader in tissue adhesive technology, has been acquired by Advanced Medical Solutions Group plc (AIM: AMS), the world’s foremost expert in tissue-healing technologies for a reported €25m consideration.

The acquisition expands AMS’s product line, strengthens its market position in the $300 million worldwide tissue adhesive industry, and greatly improves its technical and R&D capabilities in cyanoacrylate technology.

Connexicon is an expert in medical tissue adhesives with a base in Dublin. It was established in 2014 by Padraig Leamy and founded as a result of a carve-out of management, technology, and knowledge from Henkel AG & Co. KGaA. It has a technological platform that is now being sold in Europe under the brand name Indermil® Flexifuze TM, and an intriguing pipeline of new drugs aiming for US clearance by early 2024.

Advanced Medical Solutions Group PLC is a global manufacturer and distributor of wound care, surgical and wound closure products. It was established in 1991 in Cheshire, UK. In FY Dec 21 the company reported turnover of c. £108.6m which converted to c. £31.8m EBITDA.

With Connexicon’s brands, products, chemistries, knowledge, and R&D capabilities joining the Group’s extensive business partnerships, regulatory experience, and production infrastructure, the purchase strengthens AMS’s leadership position in the worldwide tissue adhesive market. The Group significantly increases its capacity to create and introduce ground-breaking adhesive and sealant innovations in the upcoming years by merging the R&D, chemistry, and cyanoacrylate expertise of both companies.

Connexicon’s products will eventually see higher sales volumes, which will result in considerable operational benefits by boosting the leverage of the Group’s current brands and assets. Additionally, when regulatory clearances are granted in the $260 million US market, expanding the commercialisation of the Indermil® portfolio and pipeline medicines through AMS’s existing, global distribution network will present additional commercial potential.

The opening of a new laboratory equipment research and development centre in Swords will result in the creation of 100 new employment by Siemens Healthineers.

It comes after the business made a multi-million dollar investment in the building where new lab equipment would be created.

Customers of Siemens Healthineers from all over the world will utilise the equipment to find cancer, blood issues, and infectious diseases.

65 of the new positions will be in engineering, with hiring expected to start immediately in fields like data science, software engineering, systems engineering, and artificial intelligence.

Since 1966, the business has operated a manufacturing operation at its Swords location, where it employs hundreds of people.

Analysers for haematology and immunoassay tests are among the equipment constructed on site and exported to more than 50 nations.

Coca-Cola Ballina recognised by World Economic Forum.

The World Economic Forum has recognised Coca-Cola Ballina as one of the most technologically advanced manufacturers and has admitted it to the organisation.

The World Economic Forum’s Global Lighthouse Network honours top manufacturers who utilise technologies from the Fourth Industrial Revolution, such as artificial intelligence, robotics, cloud computing, and big data, to boost productivity, advance sustainability, and strengthen supply chain resilience.

At the Mayo factory, formerly known as Ballina Beverages, an ambitious transformation program has been funded over several years with a large investment. This has mostly involved expenditures in cutting-edge technologies and the facility’s IT infrastructure.

The Ballina plant’s production has increased by 6.8% over the past three years, while energy use has decreased by 29%, returning emissions to 2011 levels, thanks to the site’s digital transformation and sustainability journey. Along with advances in productivity, there have also been notable cost reductions.

In 1992, Coca-Cola Ballina was founded. Along with a commercial presence in Ireland, The Coca-Cola Company also has operations in Wexford and Drogheda. Its European Operating Unit and Digital Services Hub in Dublin are also expanding. Since its founding, Coca-Cola Ballina has been a significant employer in the West of Ireland.

The workforce at Coca-Cola Ballina produces concentrates and beverage bases for Coca-Cola bottling operations throughout the world as the Company’s largest concentrate facility. The factory produces concentrates that are used to manufacture some of the most well-known brands in the world. These concentrates are sold to bottlers on four continents who then prepare and package the finished goods for customers all over the world.

A Chinese pharmaceutical company and Aerogen have teamed up to create an inhalation Covid-19 vaccination.

According to CanSinoBio, the inhaled vaccine uses a lesser dose, making vaccination of a greater number of individuals around the world more affordable.

CanSinoBio is using Aerogen’s aerosol drug delivery technology to offer a more efficient way of delivering its Convidecia vaccine. The businesses have partnered on supply and commercial development.

Convidecia Air, an inhaled vaccination, received emergency use approval as a booster dosage in China earlier this year. Shanghai was the first city to start adult booster vaccinations via inhalation in October.

Using a cup dispenser, the aerosolised vaccination is administered directly into the patient’s airway. This resembles the Covid-19 infection process in nature.

The businesses claimed that a far lower dose of the vaccine may be used to effectively administer the inhaled form of Convidecia. The CanSinoBio vaccine can now be affordably accessed by more patients than would have been possible with an injectable method.

The inhaled vaccine is currently undergoing clinical testing in Asia and Latin America, according to the two businesses. According to CanSinoBio, Morocco last week approved the use of its vaccine for emergency situations. Aerogen specialises in acute care aerosol medicine delivery, and more than 16 million patients have been treated in 75 different countries using its technology. It received the Irish Medtech Awards’ Medtech Company of the Year honour in 2020.

The Taoiseach, Micheál Martin, and Robert M. Davis, MSD’s global CEO and president, officially opened MSD Ireland’s new production facility at MSD Biotech in Swords, Co. Dublin.

Since construction on the biotech facility started in 2018, the healthcare business has invested more than €1 billion in it, and it is already essential to the production of MSD’s biologics-based medications, such as immuno-oncology.

There are now 70 unfilled opportunities, and 350 new jobs have been created since the establishment of the new location.

The pharmaceutical company has six locations in Ireland and has been operating there for many years. Approximately 3,000 employees work there. The pharmaceutical giant has just made almost $4 billion in its Irish operations.

In August of this year, MSD announced that as part of a significant expansion of its Carlow plant, it would add 100 new employees.